StabiLux is Finalist at International Convention
For the second consecutive year, StabiLux Biosciences was selected to be one of the Innovation Showcase finalists at the International CYTO convention.
CYTO, the premier meeting for the bioscience of cytometry, was held Tuesday and Wednesday (Aug. 4/5). Cytometry is a technique that detects cell structures for all biomedical fields. CYTO is organized by the International Society for Advancement of Cytometry (ISAC).
Top faculty and industry leaders showcased their innovation in various lectures, tutorials, workshops, frontiers and plenary sessions featuring cutting edge cytometry technology and applications.
Stabilux President and Chief Technical Officer Yoke Khin Yap (Physics) said CYTO, like most aspects of life, was impacted by the COVID-19 pandemic.
"The BioSciCYTO was originally planned to be held in Philadelphia during the summer, but biology threw us a curveball. Although SARS-CoV-2 may keep scientists from showcasing all the new developments in cytometry in person, CYTO Virtual 2020 filled in the gap as the first-ever virtual meeting from ISAC."
StabiLux BIosciences, an MTU spin-off company, showcased their new technology in the session of "CYTO Innovation Live Technology Showcase & Panel". CEO, Steve Tokarz, is one of top three finalists that pitched their new innovation. The new dye technology, SpectraLux and SpectraFluor, will allow scientist to detect biological molecules by the shapes of the fluorescent spectra, in addition to the peak positions of the signals. This novel feature is not found in any commercially available dyes.
The technology invented by Xiuling Liu (Physics) Nazmiye Yapici (Physics), and Dongyan Zhang (Physics) under the direction of Yap builds from their NovoLux® High-Brightness DyeTM technology licensed from the university.
The StabiLux/MTU team also presented two posters on the mechanism of NovoLux® High-Brightness Dye technology, as well as a new NovoLux® high-brightness violet dye. The company is truly enabling the next 50 years of biomedical Innovation.